In summary, this study recapitulates the multifaceted oncogenic role exerted by MUC1 in ccRCC and provides additional evidence that targeting MUC1 likely represents a novel therapeutic strategy for refractory cancers. Here, MUC1 is linked to nonpapillary renal cell carcinoma.